MCA Stability Tool

This recommendation is based on the products Abilify 10mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 10mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Arpoya 15mg tablets (Torrent Pharma (UK) Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 15mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 15mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 15mg tablets (Aurobindo Pharma - Milpharm Ltd).

Incompatible

Arpoya 5mg tablets (Torrent Pharma (UK) Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 5mg tablets suppliers

Stability Notes

Very moisture sensitive medicine. Manufacturer recommends storing in original container. Original packaging may contain desiccant.

Provenance

This recommendation is based on the products Abilify 5mg tablets (Otsuka Pharmaceuticals (UK) Ltd) and aripiprazole 5mg tablets (Aurobindo Pharma - Milpharm Ltd).

No Stability Information

Arsenicum album 30c homeopathic tablets (Ainsworths (London) Ltd)

Explore other Homeopathic arsenicum album formulations Explore other Arsenicum album 30c homeopathic tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Arsenicum album 30c homeopathic tablets (Weleda (UK) Ltd)

Explore other Homeopathic arsenicum album formulations Explore other Arsenicum album 30c homeopathic tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Arsenicum album 6c homeopathic tablets (Special Order)

Explore other Homeopathic arsenicum album formulations Explore other Arsenicum album 6c homeopathic tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Artesunate 50mg tablets (Imported (China))

Explore other Artesunate formulations Explore other Artesunate 50mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Incompatible

Arthrotec 50 gastro-resistant tablets (Lexon (UK) Ltd)

Explore other Diclofenac sodium + Misoprostol formulations Explore other Diclofenac sodium 50mg gastro-resistant / Misoprostol 200microgram tablets suppliers

Stability Notes

Very moisture sensitive.

Provenance

This compatibility recommendation is derived from Arthrotec 50 gastro-resistant tablets (Pfizer Ltd).

Incompatible

Arthrotec 50 gastro-resistant tablets (Pfizer Ltd)

Explore other Diclofenac sodium + Misoprostol formulations Explore other Diclofenac sodium 50mg gastro-resistant / Misoprostol 200microgram tablets suppliers

Stability Notes

Very moisture sensitive.

Provenance

This compatibility recommendation is derived from Arthrotec 50 gastro-resistant tablets (Pfizer Ltd).

Incompatible

Arthrotec 50 gastro-resistant tablets (Pilsco Ltd)

Explore other Diclofenac sodium + Misoprostol formulations Explore other Diclofenac sodium 50mg gastro-resistant / Misoprostol 200microgram tablets suppliers

Stability Notes

Very moisture sensitive.

Provenance

This compatibility recommendation is derived from Arthrotec 50 gastro-resistant tablets (Pfizer Ltd).

Incompatible

Arthrotec 75 gastro-resistant tablets (Pfizer Ltd)

Explore other Diclofenac sodium + Misoprostol formulations Explore other Diclofenac sodium 75mg gastro-resistant / Misoprostol 200microgram tablets suppliers

Stability Notes

Very moisture sensitive.

Provenance

This compatibility recommendation is derived from Arthrotec 75 gastro-resistant tablets (Pfizer Ltd).

No Stability Information

Arupsan 200mg tablets (Accord-UK Ltd)

Explore other Eslicarbazepine formulations Explore other Eslicarbazepine 200mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.